This activity is intended for nurses and nurse practitioners
The goal of this activity is to improve the knowledge and competence of nurses surrounding the use of immunotherapy-based treatments and poly (ADP-ribose) polymerase (PARP) inhibitors in the management of patients with triple-negative breast cancer (TNBC).
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CE Released: 11/23/2020
Valid for credit through: 11/23/2021, 11:59 PM EST
processing....
ALT = alanine aminotransferase
AST = aspartate aminotransferase
AUC = area under the curve
CPS = combined positive score
CT = computed tomography
DCR = disease control rate
DFI = disease-free interval
DOR = duration of response
ECOG PS = Eastern Cooperative Oncology Group performance status
ER = estrogen receptor
FNA = fine needle aspiration
gBRCA = germline BRCA
HER2 = human epidermal growth factor receptor 2
HRQoL = health-related quality of life
IC = immune cell
ITC = isolated tumor cell
ITT = intent-to-treat
IV = intravenous
mTNBC = metastatic triple-negative breast cancer
NCCN = National Comprehensive Cancer Network
ORR = objective response rate
OS = overall survival
PARP = poly (ADP-ribose) polymerase
PD-L1 = programmed death-ligand 1
PET = positron emission tomography
PFS = progression-free survival
PO = by mouth
PR = progesterone receptor
RCT = randomized controlled trial
TIL = tumor infiltrating lymphocyte
TNBC = triple-negative breast cancer
TRAE = treatment-related adverse event
« Return to: Nurse View: Tailoring Treatments in Triple Negative Breast Cancer |